Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome

OBJECTIVE: Metabolic syndrome refers to a collection of risk factors associated with the development of cardiovascular disease and type 2 diabetes mellitus (T2DM). Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight and blood pressure (BP) in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Metab Syndr Obes
Main Authors: Davies, Michael J, Merton, Katherine W, Vijapurkar, Ujjwala, Balis, Dainius A, Desai, Mehul
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5291455/
https://ncbi.nlm.nih.gov/pubmed/28184166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S126291
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados